Skip to main content

Table 1 Patients’ characteristics

From: Molecular characteristics and successful management of a respiratory syncytial virus outbreak among pediatric patients with hemato-oncological disease

Case Nosocomial (Yes/No) Agea (years) Sex (M/F) Underlying Disease RSV infection WBCb (per microliter) RSV Treatment, Duration (days) Additional antibiotic treatment Oxygen (Yes/No) RSV-related outcome Virus shedding (days)
1 yes 16 M Acute myeloid leukemia (recurrent) LRTI 0 oral Ribavirin, 64 Yes Yes Remission At least 63
2 yes 15 M Severe aplastic anemia LRTI 800 oral Ribavirin, 10 Yes Yes Remission 7
3 Yes 16 M Acute lymphoid leukemia URTI 1200 - Yes Yes (at night) Remission At least 6
4c Yes 9 M Post-transplant Burkitt's leukemia URTI 300 - Yes Yes Remission 17d
5 Yes 1 F Neuroblastoma URTI 9500 intravenous Ribavirin, 8 Yes Yes Remission 44
6 Possible 3 F Ewing Sarcoma URTI 500 - Yes Yes Remission 5
7 Yes 10 F Acute lymphoid leukemia URTI 700 - Yes No Remission 4
8 Possible 14 F Acute lymphoid leukemia URTI 290 oral Ribavirin, 8 Yes No Remission 13
  1. aAt time of virus detection
  2. bAt time (+/- 2 days) of virus detection
  3. cOnset of disease after discharge (treatment in home town hospital)
  4. dThere had been no in-house tests between first positive and first negative testing